Dermata Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 7.79 million compared to USD 9.61 million a year ago. Basic loss per share from continuing operations was USD 2.67 compared to USD 13.92 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3587 USD | +10.85% | +6.76% | -41.20% |
Mar. 21 | Dermata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Jan. 05 | Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-41.20% | 2.39M | |
+3.91% | 109B | |
+10.87% | 105B | |
+0.20% | 22.25B | |
-13.14% | 22.09B | |
-7.66% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- DRMA Stock
- News Dermata Therapeutics, Inc.
- Dermata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023